Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Podobne knjige/članki

• Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
  od: Jasielec, Jagoda K., et al.
  Izdano: (2020)
• Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
  od: Dimopoulos, M A, et al.
  Izdano: (2017)
• Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
  od: Dytfeld, Dominik, et al.
  Izdano: (2014)
• Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma
  od: Tadeusz Kubicki, et al.
  Izdano: (2025-11-01)
• Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
  od: Jakubowiak, Andrzej J., et al.
  Izdano: (2019)